BLA 017016 · Ferring
Chorionic Gonadotropin
Gonadotropin, Chorionic · Injection
Last checked: Nov 20, 2026Latest source record: May 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Jan 15, 1974
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,292
340 Phase 3, 113 recruiting
FAERS reports
1,179
748 serious, 30 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2025.
INDICATIONS AND USAGE HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR "NORMAL" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 15, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
6 products under this application
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 10,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 5,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 20,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
- CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 15,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Gonadotropin" as an intervention, any sponsor and status, largest first.
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00066690 · 3,066 participants · Start Dec 17, 2003 · Primary completion May 2014
Drug: Exemestane; Tamoxifen and 1 more · For: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Scottsdale, Arizona · 500 sites in all
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002651 · 3,040 participants · Start May 1995 · Primary completion Jun 2013
Drug: bicalutamide; goserelin acetate · For: Prostate Cancer
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 14 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome244
- drug ineffective94
- nausea74
- off label use68
- abdominal distension60
- headache60
- dyspnoea51
- ascites50
- vomiting44
- abortion spontaneous41
- pain40
- fatigue39
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 27 |
| 2006 | 28 |
| 2007 | 45 |
| 2008 | 20 |
| 2009 | 29 |
| 2010 | 27 |
| 2011 | 53 |
| 2012 | 81 |
| 2013 | 22 |
| 2014 | 18 |
| 2015 | 9 |
| 2016 | 44 |
| 2017 | 28 |
| 2018 | 51 |
| 2019 | 88 |
| 2020 | 56 |
| 2021 | 74 |
| 2022 | 121 |
| 2023 | 114 |
| 2024 | 72 |
| 2025 | 80 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Chorionic Gonadotropin (Chorionic Gonadotropin, Human)
2024 spending
$481K
Beneficiaries
146
598 claims
Per beneficiary
$3,291
$295.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $460,023 |
| 2021 | $387,422 |
| 2022 | $450,809 |
| 2023 | $565,015 |
| 2024 | $480,519 |
Part B: Chorionic Gonadotropin* (Chorionic Gonadotropin, Human*) · HCPCS J0725
2024 spending
$337K
Beneficiaries
241
6,848 claims
Per beneficiary
$1,398
2024 ASP limit $21.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $398,283 |
| 2021 | $504,301 |
| 2022 | $416,524 |
| 2023 | $327,448 |
| 2024 | $336,980 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anabolic steroid-induced hypogonadism: diagnosis and treatment.
Rahnema CD, Lipshultz LI, Crosnoe LE, et al. · Fertil Steril 2014 · Meta-Analysis, Review
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.
Hohl A, Chavez MP, Pasqualotto E, et al. · Arch Endocrinol Metab 2025 · Systematic Review, Meta-Analysis
- Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.
Alexander EC, Faruqi D, Farquhar R, et al. · Eur J Endocrinol 2024 · Meta-Analysis, Systematic Review
- Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis.
Christou MA, Christou PA, Markozannes G, et al. · Sports Med 2017 · Meta-Analysis, Systematic Review
- The association between human chorionic gonadotropin and adverse pregnancy outcomes: a systematic review and meta-analysis.
Peris M, Crompton K, Shepherd DA, et al. · Am J Obstet Gynecol 2024 · Meta-Analysis, Systematic Review
- Uterine infusion strategies for infertile patients with recurrent implantation failure: a systematic review and network meta-analysis.
Xie Q, Quan X, Lan Y, et al. · Reprod Biol Endocrinol 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.